<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39346557</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Quantitative pulmonary pharmacokinetics of tetrandrine for SARS-CoV-2 repurposing: a physiologically based pharmacokinetic modeling approach.</ArticleTitle><Pagination><StartPage>1457983</StartPage><MedlinePgn>1457983</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1457983</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1457983</ELocationID><Abstract><AbstractText>Tetrandrine (TET) has been traditionally used in China as a medication to treat silicosis and has recently demonstrated anti-SARS-CoV-2 potential <i>in vitro</i>. By recognizing the disparity between <i>in vitro</i> findings and <i>in vivo</i> performance, we aimed to estimate the free lung concentration of TET using a physiologically based pharmacokinetic (PBPK) model to link <i>in vitro</i> activity with <i>in vivo</i> efficacy. Comparative pharmacokinetic studies of TET were performed in rats and dogs to elucidate the pharmacokinetic mechanisms as well as discern interspecies variations. These insights facilitated the creation of an animal-specific PBPK model, which was subsequently translated to a human model following thorough validation. Following validation of the pharmacokinetic profile from a literature report on single oral dosing of TET in humans, the plasma and lung concentrations were predicted after TET administration at approved dosage levels. Finally, the antiviral efficacy of TET in humans was assessed from the free drug concentration in the lungs. Both <i>in vivo</i> and <i>in vitro</i> experiments thus confirmed that the systemic clearance of TET was primarily through hepatic metabolism. Additionally, the lysosomal capture of basic TET was identified as a pivotal factor in its vast distribution volume and heterogeneous tissue distribution, which could modulate the absorption dynamics of TET in the gastrointestinal tract. Notably, the PBPK-model-based unbound lung concentration of TET (1.67-1.74 μg/mL) at the recommended clinical dosage surpassed the <i>in vitro</i> threshold for anti-SARS-CoV-2 activity (EC<sub>90</sub> = 1.52 μg/mL). Thus, a PBPK model was successfully developed to bridge the <i>in vitro</i> activity and <i>in vivo</i> target exposure of TET to facilitate its repurposing.</AbstractText><CopyrightInformation>Copyright © 2024 Wang, Dong, Hu, Yang, Wang, Zhang, Zhang and Zhuang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Furun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Huadong Medical Institute of Biotechniques, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Liuhan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Juanwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shijie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lingchao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenpeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug repurpose</Keyword><Keyword MajorTopicYN="N">lysosomal trapping</Keyword><Keyword MajorTopicYN="N">physiologically based pharmacokinetic (PBPK)</Keyword><Keyword MajorTopicYN="N">pulmonary exposure</Keyword><Keyword MajorTopicYN="N">tetrandrine</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346557</ArticleId><ArticleId IdType="pmc">PMC11427368</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1457983</ArticleId><ArticleId IdType="pii">1457983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alsmadi M. M., Jaradat M. M., Obaidat R. M., Alnaief M., Tayyem R., Idkaidek N. (2023). The in vitro, In Vivo, and PBPK evaluation of a novel lung-targeted cardiac-safe hydroxychloroquine inhalation aerogel. AAPS PharmSciTech 24 (6), 172. 10.1208/s12249-023-02627-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-023-02627-3</ArticleId><ArticleId IdType="pubmed">37566183</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad U., Pertinez H., Box H., Tatham L., Rajoli R. K. R., Curley P., et al. (2020). Prioritization of anti-SARS-cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin. Pharmacol. Ther. 108 (4), 775–790. 10.1002/cpt.1909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1909</ArticleId><ArticleId IdType="pmc">PMC7280633</ArticleId><ArticleId IdType="pubmed">32438446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bäckman P., Arora S., Couet W., Forbes B., De Kruijf W., Paudel A. (2018). Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. Eur. J. Pharm. Sci. 113, 41–52. 10.1016/j.ejps.2017.10.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.10.030</ArticleId><ArticleId IdType="pubmed">29079338</ArticleId></ArticleIdList></Reference><Reference><Citation>Chityala P. K., Wu L., Chow D. S., Ghose R. (2020). Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model. Chem. Biol. Interact. 316, 108933. 10.1016/j.cbi.2019.108933</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2019.108933</ArticleId><ArticleId IdType="pubmed">31870839</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud N. E., Borah P., Deb P. K., Venugopala K. N., Hourani W., Alzweiri M., et al. (2021). ADMET profiling in drug discovery and development: perspectives of in silico, in vitro and integrated approaches. Curr. Drug Metab. 22 (7), 503–522. 10.2174/1389200222666210705122913</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389200222666210705122913</ArticleId><ArticleId IdType="pubmed">34225615</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies B., Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10 (7), 1093–1095. 10.1023/a:1018943613122</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1018943613122</ArticleId><ArticleId IdType="pubmed">8378254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yang C., Wang L., Xiang Y., Zhang W., Li Y., et al. (2020). Comparable intestinal and hepatic first-pass effect of YL-IPA08 on the bioavailability and effective brain exposure, a rapid anti-PTSD and anti-depression compound. Front. Pharmacol. 11, 588127. 10.3389/fphar.2020.588127</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.588127</ArticleId><ArticleId IdType="pmc">PMC7732531</ArticleId><ArticleId IdType="pubmed">33328995</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm C., Tang R. (2020). Could an endo-lysosomal ion channel be the Achilles heel of SARS-CoV2? Cell Calcium 88, 102212. 10.1016/j.ceca.2020.102212</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2020.102212</ArticleId><ArticleId IdType="pmc">PMC7201244</ArticleId><ArticleId IdType="pubmed">32402856</ArticleId></ArticleIdList></Reference><Reference><Citation>Heister P. M., Poston R. N. (2020). Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19. Pharmacol. Res. Perspect. 8 (5), e00653. 10.1002/prp2.653</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.653</ArticleId><ArticleId IdType="pmc">PMC7503088</ArticleId><ArticleId IdType="pubmed">32930523</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H. C., Chae Y. J., Shin K. H. (2022). Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling. Transl. Clin. Pharmacol. 30 (4), 201–211. 10.12793/tcp.2022.30.e20</Citation><ArticleIdList><ArticleId IdType="doi">10.12793/tcp.2022.30.e20</ArticleId><ArticleId IdType="pmc">PMC9810492</ArticleId><ArticleId IdType="pubmed">36632076</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Liu M., Liu H., Liu S. (2020). A critical review: traditional uses, phytochemistry, pharmacology and toxicology of Stephania tetrandra S. Moore (Fen Fang Ji). Phytochem. Rev. 19, 449–489. 10.1007/s11101-020-09673-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11101-020-09673-w</ArticleId><ArticleId IdType="pmc">PMC7180683</ArticleId><ArticleId IdType="pubmed">32336965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju A., Kang Y., Xue Q., Li Q. (2015). Pharmacokinetics, tissue distribution and excretion study of tetrandrine in rats. J. Chin. Pharm. Sci. 24 (08), 557–562. 10.5246/jcps.2015.08.071</Citation><ArticleIdList><ArticleId IdType="doi">10.5246/jcps.2015.08.071</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F., Wang X., Fan S., Li Y., Xu M., et al. (2023). Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19. MedComm 4 (1), e206. 10.1002/mco2.206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.206</ArticleId><ArticleId IdType="pmc">PMC9851407</ArticleId><ArticleId IdType="pubmed">36699286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q. Y., Li B., Gang J. M., Karpinski E., Pang P. K. (1995). Tetrandrine, a Ca++ antagonist: effects and mechanisms of action in vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 273 (1), 32–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew S., Tess D., Burchett W., Chang G., Woody N., Keefer C., et al. (2021). Evaluation of prediction accuracy for volume of distribution in rat and human using in vitro, in vivo, PBPK and QSAR methods. J. Pharm. Sci. 110 (4), 1799–1823. 10.1016/j.xphs.2020.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.12.005</ArticleId><ArticleId IdType="pubmed">33338491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton J. W., Theuretzbacher U., Craig W. A., Tulkens P. M., Derendorf H., Cars O. (2008). Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61 (2), 235–237. 10.1093/jac/dkm476</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkm476</ArticleId><ArticleId IdType="pubmed">18065413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., et al. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11 (1), 1620. 10.1038/s41467-020-15562-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15562-9</ArticleId><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang K. S., Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5 (6), 625–653. 10.1007/BF01059688</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01059688</ArticleId><ArticleId IdType="pubmed">599411</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathaneni V., Kulkarni N. S., Muth A., Gupta V. (2019). Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov. Today 24 (10), 2076–2085. 10.1016/j.drudis.2019.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.06.014</ArticleId><ArticleId IdType="pubmed">31238113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers T., Rowland M. (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 24 (5), 918–933. 10.1007/s11095-006-9210-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-006-9210-3</ArticleId><ArticleId IdType="pubmed">17372687</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler H. I., Knoers N., Van Haelst M. M., Van Haaften G. (2021). Drug repurposing for rare diseases. Trends Pharmacol. Sci. 42 (4), 255–267. 10.1016/j.tips.2021.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2021.01.003</ArticleId><ArticleId IdType="pubmed">33563480</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland M., Benet L. Z., Graham G. G. (1973). Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1 (2), 123–136. 10.1007/BF01059626</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01059626</ArticleId><ArticleId IdType="pubmed">4764426</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeidnia S., Manayi A., Abdollahi M. (2015). From in vitro experiments to in vivo and clinical studies; pros and cons. Curr. Drug Discov. Technol. 12 (4), 218–224. 10.2174/1570163813666160114093140</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570163813666160114093140</ArticleId><ArticleId IdType="pubmed">26778084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherbetjian E., Peters S. A., Petersson C. (2022). Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model. Xenobiotica 52 (7), 661–668. 10.1080/00498254.2022.2132427</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498254.2022.2132427</ArticleId><ArticleId IdType="pubmed">36190773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjögren E., Westergren J., Grant I., Hanisch G., Lindfors L., Lennernäs H., et al. (2013). In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur. J. Pharm. Sci. 49 (4), 679–698. 10.1016/j.ejps.2013.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2013.05.019</ArticleId><ArticleId IdType="pubmed">23727464</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsamandouras N., Rostami-Hodjegan A., Aarons L. (2015). Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br. J. Clin. Pharmacol. 79 (1), 48–55. 10.1111/bcp.12234</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12234</ArticleId><ArticleId IdType="pmc">PMC4294076</ArticleId><ArticleId IdType="pubmed">24033787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Jiang X., Yang Z., Fu S., Yao S., Wang L., et al. (2022). Alternation of organ-specific exposure in LPS-induced pneumonia mice after the inhalation of tetrandrine is governed by metabolizing enzyme suppression and lysosomal trapping. Int. J. Mol. Sci. 23 (21), 12948. 10.3390/ijms232112948</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232112948</ArticleId><ArticleId IdType="pmc">PMC9655037</ArticleId><ArticleId IdType="pubmed">36361734</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Zhang C., Hu P., Zhu M., Hu M., Gao S. (2017). An UPLC-MS/MS method for quantifying tetrandrine and its metabolite berbamine in human blood: application to a human pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1070, 92–96. 10.1016/j.jchromb.2017.10.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchromb.2017.10.048</ArticleId><ArticleId IdType="pubmed">29100757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo K. R., Zhang M., Pan X., Ban Ke A., Jones H. M., Wesche D., et al. (2020). Impact of disease on plasma and lung exposure of chloroquine, hydroxychloroquine and azithromycin: application of PBPK modeling. Clin. Pharmacol. Ther. 108 (5), 976–984. 10.1002/cpt.1955</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1955</ArticleId><ArticleId IdType="pmc">PMC7323312</ArticleId><ArticleId IdType="pubmed">32531808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R., Barth A., Wong H., Marik J., Shen J., Lade J., et al. (2022). Design and measurement of drug tissue concentration asymmetry and tissue exposure-effect (tissue PK-pd) evaluation. J. Med. Chem. 65 (13), 8713–8734. 10.1021/acs.jmedchem.2c00502</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00502</ArticleId><ArticleId IdType="pubmed">35790118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Hop C., Patilea-Vrana G., Gampa G., Seneviratne H. K., Unadkat J. D., et al. (2019). Drug concentration asymmetry in tissues and plasma for small molecule-related therapeutic modalities. Drug Metab. Dispos. 47 (10), 1122–1135. 10.1124/dmd.119.086744</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.119.086744</ArticleId><ArticleId IdType="pmc">PMC6756291</ArticleId><ArticleId IdType="pubmed">31266753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Wang F., Tang J., Nussinov R., Cheng F. (2020). Artificial intelligence in COVID-19 drug repurposing. Lancet Digit. Health 2 (12), e667–e676. 10.1016/S2589-7500(20)30192-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30192-8</ArticleId><ArticleId IdType="pmc">PMC7500917</ArticleId><ArticleId IdType="pubmed">32984792</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang X., Lu C. (2016). PBPK modeling and simulation in drug research and development. Acta Pharm. Sin. B 6 (5), 430–440. 10.1016/j.apsb.2016.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2016.04.004</ArticleId><ArticleId IdType="pmc">PMC5125732</ArticleId><ArticleId IdType="pubmed">27909650</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>